The pharmaceuticalindustry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: recombinant adeno-associated virus (rAAV) production technology. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
rAAV production technology is a key innovation area in cell & gene therapy
rAAV production technology refers to the development and optimization of methods for efficient production and modification of recombinant adeno-associated viruses (rAAVs) for gene therapy applications. This includes, but is not limited to, optimizing vector design, selecting appropriate host cells and vectors, and developing efficient purification methods for scalable production.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 360+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of rAAV production technology.
Key players in rAAV production technology – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to rAAV production technology
Company | Total patents (2021 - 2023) | Premium intelligence on the world's largest companies |
Sanofi | 560 | Unlock Company Profile |
C. H. Boehringer Sohn | 456 | Unlock Company Profile |
Voyager Therapeutics | 214 | Unlock Company Profile |
Adverum Biotechnologies | 190 | Unlock Company Profile |
UniQure | 188 | Unlock Company Profile |
Children's Hospital of Philadelphia | 154 | Unlock Company Profile |
BioMarin Pharmaceutical | 147 | Unlock Company Profile |
Zoetis | 138 | Unlock Company Profile |
Massachusetts Eye and Ear Infirmary | 137 | Unlock Company Profile |
RegenxBio | 129 | Unlock Company Profile |
Takeda Pharmaceutical | 117 | Unlock Company Profile |
F. Hoffmann-La Roche | 110 | Unlock Company Profile |
4D Molecular Therapeutics | 102 | Unlock Company Profile |
Regeneron Pharmaceuticals | 102 | Unlock Company Profile |
Genethon | 94 | Unlock Company Profile |
Sangamo Therapeutics | 84 | Unlock Company Profile |
Pfizer | 77 | Unlock Company Profile |
Eli Lilly | 75 | Unlock Company Profile |
Merck | 72 | Unlock Company Profile |
Ultragenyx Pharmaceutical | 71 | Unlock Company Profile |
Johnson & Johnson | 69 | Unlock Company Profile |
MediGene | 63 | Unlock Company Profile |
StrideBio | 60 | Unlock Company Profile |
Takara | 60 | Unlock Company Profile |
Nationwide Children's Hospital | 52 | Unlock Company Profile |
Virovek | 48 | Unlock Company Profile |
Centre National de la Recherche Scientifique | 47 | Unlock Company Profile |
Homology Medicines | 44 | Unlock Company Profile |
Virginia Tech Intellectual Property | 43 | Unlock Company Profile |
Tenaya Therapeutics | 40 | Unlock Company Profile |
Virbac Group | 38 | Unlock Company Profile |
Danaher | 35 | Unlock Company Profile |
Children's Medical Center | 35 | Unlock Company Profile |
Massachusetts General Hospital | 34 | Unlock Company Profile |
Benitec Biopharma | 33 | Unlock Company Profile |
Lonza Group | 32 | Unlock Company Profile |
Mayo Clinic | 32 | Unlock Company Profile |
City of Hope | 31 | Unlock Company Profile |
Verneuil Participations | 28 | Unlock Company Profile |
Oxford BioMedica | 27 | Unlock Company Profile |
Codiak BioSciences | 27 | Unlock Company Profile |
Applied Genetic Technologies | 27 | Unlock Company Profile |
German Cancer Research Center | 26 | Unlock Company Profile |
Fondazione Telethon | 25 | Unlock Company Profile |
MeiraGTx | 24 | Unlock Company Profile |
GE HealthCare Technologies | 21 | Unlock Company Profile |
GSK | 21 | Unlock Company Profile |
NEW HOPE, CITY OF | 21 | Unlock Company Profile |
St. Jude Children’s Research Hospital | 20 | Unlock Company Profile |
WuXi AppTec | 19 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Sanofi is one of the leading patent filers in rAAV production technology. Sanofi is a major pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, and multiple sclerosis, human vaccines for protection against various bacterial and viral diseases, and other indications. The company also offers consumer healthcare products for digestion, allergy, respiratory conditions, pain, women’s health, as well as vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. C. H. Boehringer Sohn and Voyager Therapeutics are some of the other key patent filers in rAAV production technology.
In terms of application diversity, Ultragenyx Pharmaceutical leads the pack, while Virovek and GSK stood in the second and third positions, respectively.
By means of geographic reach, Zoetis held the top position, followed by Virbac and Virginia Tech Intellectual.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.